The Unbranded Campaign

For a long time, the best those with Hemophilia A could do was rely on preventative factor replacement infusions that could offer near-normal levels of clotting for about a day at most or factor mimetic injections that offer constant, low levels of protection (that remain far below normal blood clotting standards). This would force patients to choose between constant infusions for adequate protection or risk inviting bleeds due to a lower level of protection. As a result, many patients just dealt with lower levels of protection as best they could——inviting the risk of a tragic accident and damaging their bodies over time via micro-bleeds.

Maybe more frustrating than the treatment limitation, was the prevailing attitude by physicians that Hemophilia A couldn’t or shouldn’t expect “normal” levels of clotting ability. Our unbranded campaign set out to change that mindset.